Minoryx is a registration stage biotech company focused on the development of novel therapies for orphan CNS diseases with high unmet medical needs
Minoryx is a registration stage biotech company focused on the development of novel therapies for orphan CNS diseases with high unmet medical needs. The company’s lead program, leriglitazone, is being developed in X-linked Adrenoleukodystrophy (X-ALD) and other orphan CNS diseases.